Skip to content
Longterm Wiki
Back

Science and Global Health R&D Fund – Coefficient Giving

web

Credibility Rating

4/5
High(4)

High quality. Established institution or organization with editorial oversight and accountability.

Rating inherited from publication venue: Coefficient Giving

This is a global health R&D funding page from Coefficient Giving, focused on neglected disease research including vaccines and drugs. It has minimal direct relevance to AI safety, though it mentions AI-assisted vaccine design (David Baker's Nobel Prize work), touching tangentially on AI capabilities in biomedical contexts.

Metadata

Importance: 8/100homepage

Summary

Coefficient Giving's Science and Global Health R&D Fund supports research into new tools to improve global health, focusing on neglected diseases like tuberculosis, malaria, and rheumatic heart disease. The fund covers basic research, preclinical/clinical studies, and implementation research. It has operated since 2016 and expanded its global health R&D work in 2023.

Key Points

  • Funds R&D for neglected diseases disproportionately affecting the world's poorest populations, where funding gaps are 10x or more relative to disease burden.
  • Supports transformative basic research, clinical trials for new treatments/vaccines/diagnostics, and implementation research.
  • Launched an RFP for generic drug repurposing to accelerate treatment options for high-burden neglected diseases.
  • Highlights AI-assisted vaccine design, including grantee David Baker's Nobel Prize-winning protein design work.
  • Partners include Good Ventures, Patchwork Collective, and private funders.

Cached Content Preview

HTTP 200Fetched Apr 11, 20265 KB
Science and Global Health R&D

 
 We support research and development into new tools to improve global health. 

 
 
 
 
 
 
 
 Contents

 
 About the Fund 

 Research & Updates 

 Featured Grants 

 
 
 
 
 
 
 
 
 
 
 

 About the Fund

 
 
 

 Team

 
 
 
 
 
 
 
 
 
 Chris Smith 
 Program Director

 
 

 
 
 
 
 
 
 
 Chris Somerville 
 Program Director

 
 

 
 
 
 
 
 
 
 Heather Youngs 
 Program Director

 
 

 
 
 
 
 
 
 
 Katharine Collins 
 Senior Program Officer

 
 

 
 
 
 
 
 
 
 Ray Kennedy 
 Senior Program Officer

 
 

 
 
 
 
 
 
 
 Aisling Leow 
 Associate Program Officer

 
 

 
 
 
 
 
 
 
 Rafael Dib 
 Senior Program Associate

 
 

 
 
 
 

 Partners

 
 
 
 
 Good Ventures 

 Patchwork Collective 

 Private funders (x3) 

 
 
 Interested in learning more or joining the fund? Reach out to partnerwithus@coefficientgiving.org .

 

 

 
 
 
 

 
 Health technologies like vaccines and drugs save millions of lives around the world. Yet many cures remain undiscovered. Government and private sector funders do not always prioritize research and development (R&D) that could help the most people live long and healthy lives. 

 Diseases like tuberculosis, malaria, and rheumatic heart disease that primarily affect the world’s poorest people receive much less R&D spending relative to their health burdens than diseases affecting the wealthy. High-risk, transformational science often goes unfunded, too.  

 We are particularly interested in supporting products or fields where progress has stalled, where additional resources could accelerate breakthrough discoveries and new tools for global health. 

 We have supported scientific research for human health since 2016, expanding our work in global health R&D in 2023. Our work includes: 

 
 Transformative basic research and tool development aimed at answering fundamental questions about biology and human health. 

 Preclinical and clinical studies to develop and test new treatments , vaccines , diagnostics , and other preventive technologies .

 Implementation research , technical assistance , and market-shaping initiatives to help health systems make use of the best knowledge and tools available, and expand the availability of lifesaving technologies.

 

 

 
 

 
 
 
 
 
 
 
 Request for Proposals

 RFP on Generic Drug Repurposing

 
 
 
 Coefficient Giving is launching a Request for Proposals to fund rigorous investigations of repurposed generic drugs for high-burden yet neglected diseases. We are seeking proposals to move promising candidates toward clinical evidence of efficacy — leveraging the speed, cost, and access advantages that repurposing offers to deliver new treatment options for patients who cannot wait for the next generation of drug discovery.

 
 
 Read more
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Research & Updates

 
 
 Prev 
 
 
 Next 
 
 
 

 
 
 

 
 
 Blog

 
 
 
 
 A Quantitative Approach to Vaccine Funding
 
 
 
 

 
 
 

 
 Some diseases that kill many people re

... (truncated, 5 KB total)
Resource ID: 05f410ae12bd5fdb